Discover open access scientific publications

Search, annotate, share and cite publications

Publications by S. Oizumi

OA08.01 Long-Term Efficacy and Safety of Nivolumab in Second- Or Third-Line Japanese Malignant Pleural Mesothelioma Patients (Phase II: MERIT Study)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P2.01-005 a Randomized Phase II Trial of Erlotinib vs S-1 in Patients With NSCLC as Third- Or Fourth-Line Therapy (HOT1002)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2017English

Related publications

Vinorelbine and Gemcitabine as Second- Or Third-Line Therapy for Malignant Pleural Mesothelioma

Lung Cancer
Cancer ResearchOncologyRespiratory MedicinePulmonary
2014English

Phase II Study of Cediranib in Patients With Malignant Pleural Mesothelioma: SWOG S0509

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2011English

Phase II Study of Belinostat (PXD101), a Histone Deacetylase Inhibitor, for Second Line Therapy of Advanced Malignant Pleural Mesothelioma

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2009English

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of Tremelimumab for Second and Third Line Treatment in Patients With Unresectable Pleural or Peritoneal Mesothelioma

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2013English

Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Novel Therapies in Phase II and III Trials for Malignant Pleural Mesothelioma

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2012English

P1.09-011 LUME-Meso Phase II/III Study: Nintedanib + Pemetrexed/Cisplatin in Chemo-Naïve Patients With Malignant Pleural Mesothelioma

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2017English

Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) as Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2016English

P1.04-29 Second or Third Line Nivolumab Versus First Line Nivolumab in Patients With Previously Treated Advanced Non Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy